Literature DB >> 20368554

Resectable esophageal cancer: surgery as primary therapy is not the answer, but then, what is and why?

Jaffer A Ajani.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20368554     DOI： 10.1200/JCO.2009.26.7591

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience.

Authors:  Panteleimon Kountourakis; Arlene M Correa; Wayne L Hofstetter; Jeffrey H Lee; Manoop S Bhutani; David C Rice; Ritsuko Komaki; Dipen M Maru; William A Ross; Ara Vaporciyan; Stephen G Swisher; Jaffer A Ajani
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

2.  Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.

Authors:  J A Ajani; A M Correa; W L Hofstetter; D C Rice; M A Blum; A Suzuki; T Taketa; J Welsh; S H Lin; J H Lee; M S Bhutani; W A Ross; D M Maru; H A Macapinlac; J Erasmus; R Komaki; R J Mehran; A A Vaporciyan; S G Swisher
Journal:  Ann Oncol       Date:  2012-07-24       Impact factor: 32.976
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.